Huge variations between countries in time for reimbursement decisions on new cancer drugsAccessOctober 20, 2018
Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarilyAccessJanuary 28, 2017
EMA reconsiders and gives its positive opinion for the approval of ixazomibAccess, MyelomaSeptember 17, 2016
MPE encourages EMA to review its negative recommendation for ixazomibAccess, MPE, MyelomaAugust 16, 2016
